STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 233.6

Change

-0.70 (-0.30)%

Market Cap

USD 0.72B

Volume

115.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.59 (-1.29%)

USD 63.97B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-1.60 (-0.30%)

USD 13.03B
WRD:PA HSBC ETFs Public Limited Compa..

-0.13 (-0.37%)

USD 10.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-1.86 (-0.76%)

USD 8.86B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-1.90 (-0.41%)

USD 8.07B
WLD:PA Lyxor UCITS MSCI World D-EUR

-1.36 (-0.39%)

USD 7.15B
HHH:PA HSBC ETFs Public Limited Compa..

-0.15 (-0.28%)

USD 7.09B
LCWD:PA Multi Units Luxembourg - Lyxor..

-0.08 (-0.43%)

USD 6.59B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-0.81 (-0.21%)

USD 5.43B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

-0.06 (-0.04%)

USD 5.00B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.36% 67% D+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.36% 67% D+ 74% C
Trailing 12 Months  
Capital Gain 19.93% 40% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.93% 40% F 60% D-
Trailing 5 Years  
Capital Gain 61.17% 71% C- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.17% 71% C- 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.63% 58% F 60% D-
Dividend Return 8.63% 57% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.38% 73% C 86% B+
Risk Adjusted Return 102.92% 98% N/A 96% N/A
Market Capitalization 0.72B 74% C 76% C+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike